ReviewOxidative medicine and cellular longevity2026
Ebselen: A Multifaceted Organoselenium Compound With Therapeutic Potential in Liver Diseases.
Review in Oxidative medicine and cellular longevity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ebselen: A Multifaceted Organoselenium Compound With Therapeutic Potential in Liver Diseases.Oxidative medicine and cellular longevity · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Both oxidative stress and inflammation are considered the driving mechanisms in most liver pathologies. Therefore, identifying pharmacological compounds with antioxidant and anti-inflammatory properties is central to curbing hepatic diseases. Ebselen is a synthetic organoselenium compound with glutathione peroxidase (GPx)-like activity, demonstrating potent antioxidant and anti-inflammatory effects experimentally. Ebselen targets several molecular mechanisms involved in hepatic cellular injury. It maintains redox-sensitive signaling, neutralizes reactive free radicals, and regulates thiol-dependent enzymes in experimental models of drug-induced, ischemia-reperfusion, and metabolic liver diseases. Studies provided experimental evidence for Ebselen's role in suppressing lipid peroxidation, preserving mitochondrial dynamics, inhibiting inflammatory response, and protecting hepatocytes in cell lines as well as murine models of different liver injuries. Findings also reported an indirect effect on cellular demise and fibrogenesis through inhibiting the activation of hepatic stellate cells (HSCs) and decreasing collagen deposition. The hepatoprotective effects of Ebselen also extend to include reducing hepatic lipid accumulation and preventing steatosis induction in rodent models of liver fibrosis. This review summarizes the current available evidence on the hepatoprotective effects of Ebselen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.